Metastatic renal carcinoma comprehensive prognostic system
about
C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic ReviewPredictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinomaThe Multifaceted Roles Neutrophils Play in the Tumor MicroenvironmentPredicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.Metastatic renal cell cancer treatments: an indirect comparison meta-analysis.Prognostic effect of serum C-reactive protein kinetics on advanced renal cell carcinoma treated with sunitinib.A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancerExpression level of dihydropyrimidine dehydrogenase is associated with clinical outcome in patients with T1G3 bladder cancer treated with Bacillus Calmette-Guerin.MiR-200a regulates epithelial to mesenchymal transition-related gene expression and determines prognosis in colorectal cancer patientsValidation of CRP as prognostic marker for renal cell carcinoma in a large series of patients.Prognostic factors for overall survival with targeted therapy in Chinese patients with metastatic renal cell carcinoma.New prognostic factors and scoring system for patients with skeletal metastasis.Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma.The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancerPre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patientsPrognostic impact of platelet/lymphocyte and neutrophil/lymphocyte ratios in patients with gastric cancer: a multicenter studyEpidemiology of renal cell carcinoma.Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United StatesDown-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancerPrognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group.The neutrophil/lymphocyte ratio is an independent prognostic indicator in patients with bone metastasis.Prognostic Value of Serum Lactate Dehydrogenase in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.Evaluation of neutrophil-to-lymphocyte ratio prior to prostate biopsy to predict biopsy histology: Results of 1836 patients.The prognostic significance of preoperative leukocytosis and neutrophil-to-lymphocyte ratio in patients who underwent radical cystectomy for bladder cancerBasal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors.Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma.Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable.Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial.The longitudinal relationship between circulating concentrations of C-reactive protein, interleukin-6 and interleukin-10 in patients undergoing resection for renal cancer.Monocytes and neutrophils as 'bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma--results from a randomised phase II trialAn approach to estimating prognosis using fractional polynomials in metastatic renal carcinoma.Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model.Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy.Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients.Is treatment with interferon-alpha effective in all patients with metastatic renal carcinoma? A new approach to the investigation of interactions.Prognostic factors in renal cell cancer.Outcomes and prognosis in advanced renal cell carcinoma.Blood neutrophil-to-lymphocyte ratio is prognostic in gastrointestinal stromal tumor.A comprehensive prognostic stratification for patients with metastatic renal clear cell carcinoma.Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma.
P2860
Q26771557-82F559FB-7C97-4575-A32E-00F1465E9C69Q28067482-A65F9446-8AD0-4822-99CF-C6B9E7E6BB6CQ28241308-2F315442-91C8-4D76-ACAD-9895847721C3Q33317794-F1DC1635-19F1-40AE-AF70-2C0E720DF3AAQ33403399-9E83E123-ED31-4C4A-BD9A-71FAEEFDF2A7Q33685968-FB34D93A-6AE4-4646-9A48-6765103E7685Q34023737-A91D53C5-8D27-4509-A6EC-850277907C5AQ34217487-FAFCCE80-A48C-4DF7-A027-5E7604DB4202Q34402921-C646A10C-CCA9-4197-9A1F-6FD14D8979A2Q34408625-24C9BB60-E0DB-4091-962C-E84304D57A28Q34602155-254B7341-7DA9-4DA2-98BF-0453AA6C01D0Q34998576-68DA28E7-72B9-4FD2-A540-567A77E692D3Q35010248-929A4A4D-3CFE-42B1-B4EE-77CEE0DBDBB9Q35551037-A3899DE4-F61F-4EF8-AD6A-B3F758FF8BC9Q35595696-2D96475E-21E4-4CB8-ABF8-00D29C56F493Q35791350-92EDF371-66EC-4840-A7C8-E913264FD9E2Q35851652-04F67105-5A18-4799-8741-9DD97E559C2DQ35887353-DC928F17-41B2-4891-931C-8EE63E586C65Q35998435-14B5BD36-1AFD-4AC9-8689-F87B6FDD935FQ36071421-11330B3F-BA74-483F-84C6-623EDAE46897Q36120942-5AB9BC7F-FC9F-4AEF-95E2-44B7E8D346EAQ36197277-E2324BD4-3BD0-42EC-9B5D-7D7CAA3F2A01Q36264770-52FB6EEA-C041-4C49-A559-DB326D60A1EBQ36264797-CC05E123-20E5-4C4C-AA4F-A7ED991C9E8AQ36316017-8C34408B-89F9-46BC-AC3C-E5AD775A9F0CQ36532950-32474A02-8C38-4027-AB69-F05C0043C341Q36611650-F073D387-54B9-4DF8-80B4-8D106E1BCA16Q36611853-8653A710-A24E-4BE9-A2F2-834BBBD33E3DQ36612383-0501E872-16FD-4263-A9A3-2241753F1673Q36613642-4AB58BBE-8448-4C8B-B453-F6F66E73A701Q36614380-0E07C0DE-07DA-42A6-AE7B-9E752EC87B29Q36615128-77B5EAF9-28CB-4BE5-84B4-2C2D6A31A5A9Q36615307-8DAEF56A-EFED-48F7-8814-DFEE4F0CB0FEQ36663605-53EC7B99-0127-4F08-8022-FF6D55F8B1A7Q36696792-B9B5A514-53FD-44A2-B0EB-07CA5D635ED4Q36794803-F826E211-1072-460B-B4DB-CEAE4548C459Q36842773-A473A698-581F-4128-9AD6-C2392C5D9960Q36979386-32173807-9C34-4B5A-BEA0-347AF7A38617Q37041069-29A979E3-D7B7-4D54-88D1-6B794013FCCDQ37205794-577DA104-1DF1-4275-9BA5-78231B43B8F3
P2860
Metastatic renal carcinoma comprehensive prognostic system
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2003
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Metastatic renal carcinoma comprehensive prognostic system
@en
Metastatic renal carcinoma comprehensive prognostic system.
@nl
type
label
Metastatic renal carcinoma comprehensive prognostic system
@en
Metastatic renal carcinoma comprehensive prognostic system.
@nl
prefLabel
Metastatic renal carcinoma comprehensive prognostic system
@en
Metastatic renal carcinoma comprehensive prognostic system.
@nl
P2093
P2860
P356
P1476
Metastatic renal carcinoma comprehensive prognostic system
@en
P2093
DGCIN -- German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group
J Atzpodien
P2860
P2888
P304
P356
10.1038/SJ.BJC.6600768
P407
P577
2003-02-01T00:00:00Z